The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...

MRI of inhaled perfluoropropane can assess regional lung ventilation and monitor improvements in response to medication ...

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing drugs, according to a new study.

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing drugs, according to a new ...

Unveiling the Molecular Impact of Smoking on Lung Health. This illustration explores how smoke components in cigarette and ...

Cigarette smoking is widespread and deadly, yet our understanding of how cigarette smoke actually causes serious respiratory ...

Inc., an integrated clinical-stage biopharmaceutical company dedicated to developing inhaled medicines, today announced the ...

In a new webinar, industry experts explore how innovative technology and direct patient communication are transforming medication adherence in the UK.

New evidence has linked PM1 pollution to significant increases in hospitalizations for COPD and pneumonia, with older adults ...

Dupixent® is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in ...

Sanofi (SYN) 43rd Annual J.P. Morgan Healthcare January 14, 2025 12:45 PM ETCompany ParticipantsPaul Hudson - Chief Executive OfficerFrancois-Xavier Roger ...